[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-infertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-infertility":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,52,79,109,133,159,189,212,236,260,288,312,338,370,394,416,440,461,487,519],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641313","hippo-related-competing-endogenous-rna-cerna-network-dysregulation-and-in-vitro-fertilization-ivf-outcomes-in-women-with-diminished-ovarian-reserve-100641313",false,"NCT07658846","Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve","Investigating the Dysregulation of the Hippo-Related ceRNA Network and Its Impact on IVF Outcomes in Patients With Diminished Ovarian Reserve (DOR)","DOR-HIPPO-IVF","Inclusion Criteria:\n\n* Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles.\n* Infertility duration of at least one year\n* Primary or secondary infertility.\n\nExclusion Criteria:\n\n* Polycystic Ovary Syndrome (PCOS)\n* Endometriosis.\n* Ovarian tumors or malignancy.\n* Severe systemic diseases affecting fertility.\n* Metabolic syndrome.\n* Connective tissue disorders.\n* Hormonal therapy within the last three months.\n* Refusal to participate.","FEMALE","18 Years","40 Years",{"count":21,"type":22},70,"ESTIMATED","OBSERVATIONAL","Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.\n\nThis prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.",[26,27,28],"Diminished Ovarian Reserve","Female Infertility","In Vitro Fertilization",[30,31,32,33,34,35,36,37,38],"Diminished Ovarian Reserve (DOR)","In Vitro Fertilization (IVF)","Hippo Signaling Pathway","Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)","microRNA-181a-5p","Yes-Associated Protein 1 (YAP1)","Connective Tissue Growth Factor (CTGF)","Insulin-Like Growth Factor 1 (IGF1)","Follicular Fluid","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":22},"2026-08-01",{"date":47,"type":22},"2028-10-01",{"name":49,"class":50},"Assiut University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100265925","phase-2-uterine-transplant-in-absolute-uterine-infertility-auif-100265925","NCT02741102","Uterine Transplant in Absolute Uterine Infertility (AUIF)","Uterine Transplant Inclusion\u002FExclusion Criteria\n\nRECIPIENT:Inclusion Criteria\n\n* Age 18-40\n* Clinical evidence of AUFI (Absolute Uterine Factor Infertility)\n* Able to produce at least 6 normal embryos by IVF for future use\n* Reasonable weight with BMI (Body Mass Index) less than 30.\n* Normal kidney function\n* Able to undergo transplant and be compliant with treatment\n* Has stable partner and social supports\n* Partner willing to undergo psychological evaluation and receive immunizations as recommended\n* Stable home environment to support a child\n\nExclusion Criteria :\n\n* Active smoking, alcohol use or use of illicit drugs\n* Inability to comply with required treatment (taking pills, having biopsies, frequent appointments )\n* Having a condition that would make pregnancy or taking anti rejection medicines too risky.\n* Active infection: Human Immunodeficiency Virus (HIV) , Tuberculosis, Hepatitis B, Hepatitis C\n* History of extensive abdominal or pelvic surgery\n* History of abnormal Papanicolaou test (PAP smear) or genital warts\n* History of pelvic inflammatory disease\n\nDONOR:Inclusion criteria\n\n* Age over 40 up to age 60\n* Has completed having a family\n* Previous pregnancies were carried to term (no miscarriages)\n* Able to take a birth control pill containing estrogen\n* Weight reasonable with BMI (Body Mass Index) of 30 or less\n* Good social supports\n\nExclusion Criteria:\n\n* Active smoking, alcohol use or use of illicit drugs\n* Psychiatric illness\n* Cervical or endometrial polyps (growths) or tumors in the uterus muscle\n* History of more than 1 Caesarean section\n* History of abnormal PAP smear or genital warts\n* Internal scarring from extensive abdominal or pelvic surgery\n* Hypertension, Coronary artery disease, Chronic Obstructive Lung disease (emphysema) and Diabetes\n* Active cancer or incompletely treated cancer\n* Active infection including Human Immunodeficiency Disease (HIV) , Tuberculosis, Hepatitis B or Hepatitis C\n* Significant history of either blood clots or bleeding tendencies\n* Evidence of coercion or exchange of money or goods for donating the organ",{"count":59,"type":22},10,"INTERVENTIONAL",[62,63],"PHASE2","PHASE3","This study will examine the feasibility of initiating a uterine transplant program for Absolute Uterine Factor Infertility (AUFI) at Brigham and Women's Hospital. The investigators plan to screen 30 patients with a goal of enrolling 10 patients. (5 donors and 5 recipients) After careful screening, appropriate candidates will undergo IVF, Uterine Transplantation, Embryo Transfer, Pregnancy and Delivery. Once the uterus is explanted, five years of follow-up is planned.",[27],[67,68],"Infertility","AUFI","RECRUITING","2026-04-22",{"date":72,"type":43},"2026-04-28",{"date":74,"type":22},"2026-05",{"date":76,"type":22},"2028-01",{"name":78,"class":50},"Brigham and Women's Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":87,"targetDuration":4,"studyType":60,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100634662","effect-of-comprehensive-spa-rehabilitation-on-female-infertility-a-clinical-study-in-adult-women-infertility-spa-100634662","NCT07542600","Effect of Comprehensive Spa Rehabilitation on Female Infertility: A Clinical Study in Adult Women (Infertility-Spa)","Objective Assessment of the Effect of Comprehensive Spa Rehabilitation Care on Female Infertility: A Prospective Interventional Clinical Study","Inclusion Criteria:\n\n* Female, age 20-40 years\n* Diagnosis of infertility (primary or secondary)\n* History of at least one unsuccessful embryo transfer\n\nExclusion Criteria:\n\n* Contraindications to spa treatment\n* Acute gynecological inflammation\n* Severe comorbidities affecting study outcomes\n* Oncological disease\n* Alcohol intake \\>20 g\u002Fday\n* Non-compliance with treatment\n* Diagnosed with endometriosis","20 Years",{"count":88,"type":22},55,[90],"NA","This is a prospective, single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa treatment (Komplexní lázeňská léčebně rehabilitační péče, KLP) on female infertility at spa facility in Františkovy Lázně, Czech Republic.\n\nThe study enrolls 55 women aged 20-40 years diagnosed with infertility. The primary objective is to assess changes in hormonal profile before and after treatment.\n\nSecondary objectives include evaluation of body composition, psychometric outcomes and long-term reproductive outcomes.",[27,93,94],"Reproductive Disorders","Recurrent Pregnancy Loss",[96,97,27,98,99],"Spa Treatment","Balneotherapy","Hormonal Profile","IVF Preparation","2026-04-17",{"date":102,"type":43},"2026-04-21",{"date":104,"type":22},"2026-04-15",{"date":106,"type":22},"2028-01-01",{"name":108,"class":50},"Institute of Spa and Balneology, public research institution",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":60,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":51},"100634966","clinical-relevance-of-modifying-rankl-signaling-during-folliculogenesis-100634966","NCT07546552","Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis","Inclusion Criteria:\n\n* Female in the age of 18 or above, Normal AMH-value, able to give concent\n\nExclusion Criteria:\n\n* Patients who have had autotransplanted ovarian tissue",true,{"count":117,"type":22},100,[90],"Female infertility presents a significant societal challenge that will be aggravated in the future due to delayed parenthood. Our translational research suggests that receptor activator of NF-κB ligand (RANKL) is a novel treatment target, during assisted reproductive techniques and that inhibition of this pathway may reduce the impact of aging on the ovary. RANKL is a regulator of bone health, and an antibody (denosumab) blocking RANKL activity is used clinically to treat osteoporosis. Previously, we have shown that inhibition of RANKL increases sperm production in rodents, in human tissue models, and in a subpopulation of infertile men. Now, we show that all factors of the RANKL signalling system are expressed in human and mouse ovaries. Granulosa cell-specific Rankl knockdown lowers the number of primordial follicles, which suggests that RANKL has an important role during early stages of folliculogenesis. Additionally, our data from women undergoing in vitro fertilisation show that follicular fluid concentrations of RANKL and OPG are associated with age and the number of matured follicles, and RANKL inhibition promoted maturation of human oocytes in vitro, which suggests an effect also late in folliculogenesis. Thus, the proposed project aims to: 1) Clarify the role of RANKL in ovaries of mice and humans 2) Determine the reproductive effect of modulating RANKL activity systemically or locally in mice and monkeys 3) Investigate whether manipulation of RANKL can optimise in vitro maturation and rescue of immature human oocytes and 4) Determine whether follicular fluid concentrations of soluble RANKL and OPG may serve as markers of ovarian pathophysiology. The overall aim of this project is to uncover how RANKL regulates follicle reserve and oocyte maturation during the final stages of follicle development. Thereby, determining whether this pathway may be a target for optimisation of IVF treatment and a future treatment option for female infertility.",[27,121,122,123,124],"NF-κB Ligand","RANKL","Osteoporosis","Follicle Development","2026-04-16",{"date":70,"type":43},{"date":128,"type":43},"2025-08-01",{"date":130,"type":22},"2028-03-15",{"name":132,"class":50},"Peter Humaidan",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":60,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":51},"100634092","endometrial-immune-profile-changes-after-autologous-intrauterine-prp-treatment-100634092","NCT07535190","Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment","Prospective Study on Endometrial Immune Profile Changes After Autologous Intrauterine Platelet Rich Plasma (PRP) Treatment","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having infertility\n* Having regular menstrual cycles\n* Embryo transfer of euploid embryos\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial Bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Cancer diagnostics\n* Positive HIV, HCV or HBV tests\n* Autoimmune diseases\n* Recent immune therapy","50 Years",{"count":142,"type":22},50,[90],"The success rate after treatment by in-vitro fertilisation (IVF) strongly depends on the endometrial receptivity, which in turn is strictly connected to the endometrial immune profile. IVF outcome is largely dependent upon endometrial immune cell ratios and their relationship with one another.\n\nDuring the last few years there are several studies and case reports for intrauterine PRP application in patients resulting in a thicker, regenerated endometrium and better immune cell population ratios.\n\nIn this project, the investigators aim to analyze the effect of autologous intrauterine PRP administration on the endometrial immune profile, endometrial thickness, selected hormone levels (E2, P4) during the mid-luteal phase and IVF outcomes (biochemical and clinical pregnancy).",[146,27],"IVF Patients",[148,149,150],"PRP","endometrium","IVF outcomes","2026-04-14",{"date":100,"type":43},{"date":154,"type":43},"2026-01-19",{"date":156,"type":22},"2028-06",{"name":158,"class":50},"Nadezhda Women's Health Hospital",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":60,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":51},"100631412","day-4-embryo-defragmentation-blastocyst-rate-and-clinical-outcomes-100631412","NCT07500337","Day-4 Embryo Defragmentation: Blastocyst Rate and clInical Outcomes","Effect of Embryo Defragmentation on Day 4 (D4) on Blastocyst Development Rate and Clinical Outcomes in ART Cycles: a Prospective RCT","DEBRIS","Inclusion Criteria:\n\n1. Female patients undergoing ICSI cycles at the participating center\n2. Age 18-42 years\n3. Presence of at least one morula with cytoplasmic fragmentation ≥10% at Day 4 morphological assessment (Grade B: 10-25%, Grade C: 26-50%, Grade D: ≥50%)\n4. Embryos intended for extended culture to blastocyst stage (Day 5\u002FDay 6)\n5. All embryo cultures performed in time-lapse incubator (Geri, Genea Biomedex)\n6. Written informed consent obtained prior to any study-related procedure -\n\nExclusion Criteria:\n\n1. Severely reduced ovarian reserve (AMH ≤ 0.5 ng\u002FmL)\n2. Body mass index (BMI) ≥ 32 kg\u002Fm²\n3. Diagnosis of endometriosis\n4. Polycystic ovary syndrome (PCOS)\n5. Maternal age ≥ 42 years\n6. History of repeated implantation failure\n7. Donor gamete cycles (oocyte or sperm donation)\n8. Cycles with preimplantation genetic testing for monogenic disease (PGT-M) as primary indication\n9. Embryos with severe morphological compromise at Day 3\n10. Concurrent participation in other interventional studies that could interfere with study outcomes\n11. Inability to provide written informed consent","42 Years",{"count":169,"type":22},320,[90],"Background:\n\nEmbryo fragmentation is one of the main morphological parameters assessed during in vitro culture in assisted reproductive technology (ART). The presence of anucleate cytoplasmic fragments is commonly observed in human embryos and may negatively affect developmental potential and clinical outcomes. Embryo defragmentation at early stages (Day 2-3) is an established technique in some centers, but evidence remains heterogeneous. Defragmentation at Day 4 (morula\u002Fcompaction stage) represents a significantly less explored area, with promising but insufficient data to guide clinical practice.\n\nStudy Objective:\n\nThis study aims to evaluate whether mechanical or laser-assisted embryo defragmentation performed on Day 4 (D4) of in vitro culture improves blastocyst development rates and clinical outcomes in ART cycles, compared to standard culture without intervention.\n\nStudy Design:\n\nThis is a prospective, randomized controlled trial (RCT) with single-blind assessment. Patients undergoing IVF\u002FICSI with embryos showing ≥10% fragmentation at D4 morphological evaluation will be randomly assigned (1:1 ratio) to one of two groups:\n\nGroup A (Intervention): Mechanical\u002Flaser defragmentation at D4, followed by standard blastocyst culture Group B (Control): Standard blastocyst culture without any additional manipulation\n\nRandomization will be performed at the patient level using pre-generated block randomization lists, stratified by patient age (\\\u003C35 vs. ≥35 years), number of fragmented embryos at D4, and use of preimplantation genetic testing (PGT-A).\n\nParticipants:\n\nWomen aged 18-43 years undergoing IVF\u002FICSI cycles, with at least one embryo showing ≥10% fragmentation at D4 and destined for blastocyst culture. Key exclusion criteria include: donor gamete cycles, PGT-M as primary indication, embryos with \\>50% fragmentation, or severe morphological compromise at Day 3.\n\nPrimary Outcome:\n\nRate of usable blastocysts (Gardner score ≥3BB) per embryo included in the study, assessed at Day 5 and Day 6 of culture.\n\nSecondary Outcomes:\n\nOverall blastocyst development rate (D5\u002FD6), Gardner score distribution, blastocyst cryopreservation rate, implantation rate, clinical pregnancy rate (heartbeat at 7 weeks), ongoing pregnancy rate (beyond 12 weeks), live birth rate per transfer, and morphokinetic analysis (if time-lapse incubator available).\n\nSample Size:\n\nApproximately 240 patients total (120 per arm), based on an expected blastocyst rate of \\~42% in the control group vs. \\~57% in the intervention group (15% absolute difference), with 80% power and α=0.05. A 15% dropout correction is applied.\n\nDuration:\n\n6 months of enrollment plus 6 months of clinical follow-up (total \\~12 months).",[27,173,28],"Embryo Development",[175,176,177,178,179,180],"Embryo defragmentation","Blastocyst development","Embryo fragmentation","ICSI","Embryo culture","Randomized controlled trial","2026-03-24",{"date":183,"type":43},"2026-03-30",{"date":181,"type":43},{"date":186,"type":22},"2026-12-31",{"name":188,"class":50},"Momo Fertilife",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":197,"targetDuration":4,"studyType":60,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":51},"100623276","comparison-of-ivf-outcomes-between-ppos-and-antagonist-protocols-in-women-with-pcos-100623276","NCT07394530","Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS","A Comparative Study of In Vitro Fertilization Outcomes Between PPOS and Antagonist Protocols in Women With Polycystic Ovary Syndrome","PPOS-PCOS-IVF","Inclusion Criteria:\n\n* Women aged 18-40 years\n* Diagnosed with polycystic ovary syndrome (PCOS) according to the modified Rotterdam criteria (2004) (≥2 of 3: oligo\u002Fanovulation, hyperandrogenism, or polycystic ovarian morphology on ultrasound)\n* Indicated for in vitro fertilization (IVF) due to PCOS alone or PCOS with other infertility factors (e.g., tubal factor, previous failed IUI)\n* Eligible for controlled ovarian stimulation for IVF\n* Husband\u002Fpartner with normal sperm parameters or mild to moderate oligoasthenoteratozoospermia (OAT)\n* Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Uterine abnormalities that may impair implantation or pregnancy outcomes, including congenital uterine malformations, large fibroids distorting the uterine cavity, adenomyosis, or severe intrauterine pathology.\n* History of major ovarian or uterine surgery affecting ovarian reserve or uterine structure (e.g., ovarian cystectomy, endometriosis surgery, myomectomy, unilateral oophorectomy)\n* History of recurrent pregnancy loss (≥3 spontaneous miscarriages)\n* Known chromosomal abnormalities in either partner\n* Inability to adhere to study protocol or follow-up procedures",{"count":198,"type":22},400,[90],"This study aims to compare the outcomes of two ovarian stimulation protocols used in in vitro fertilization (IVF): the progestin-primed ovarian stimulation (PPOS) protocol and the GnRH antagonist protocol.",[202,27],"Polycystic Ovary Syndrome (PCOS)","2026-02-09",{"date":205,"type":43},"2026-02-11",{"date":207,"type":43},"2026-01-20",{"date":209,"type":22},"2028-06-30",{"name":211,"class":50},"Hanoi General Hospital (Vietnam)",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":222,"studyType":23,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":51},"100618428","establishing-a-minimum-predictive-threshold-follicular-size-and-oocyte-retrieval-in-icsi-cycle-100618428","NCT07331493","Establishing a Minimum Predictive Threshold Follicular Size and Oocyte Retrieval in ICSI Cycle","Follicular Size and Oocyte Retrieval in ICSI Cycle : Establishing a Minimum Predictive Threshold. A Prospective Cohort Study","Inclusion Criteria:\n\n* women aged 18 to 35 years undergoing ICSI.\n* at least four follicles above 15 mm in diameter on the day of trigger\n* Downregulation using either GNRH antagonist or agonist protocol\n* Provision of written ,informed consent\n* BMI 18 to 35 kg per meter square\n\nExclusion Criteria:\n\n* anticipated poor responder, according to Bologna criteria\n* cycle canceled prior to retrieval or without trigger administration\n* Oocyte cryoperservation cycles or natural IVF cycles\n* presence of ovarian pathology affecting the follicular assessment (endometriosis,cysts )","35 Years",{"count":221,"type":22},60,"7 Weeks","This study uses number and size of ovarian follicles on the day of ovulation trigger as key determinants for oocytes yield to optimize outcomes in IVF and ICSI Protocols",[27],[178,226,227,228,229],"Follicular size","Oocyte Retrieval","Oocyte yield","assisted reproduction",{"date":205,"type":43},{"date":232,"type":22},"2026-04-30",{"date":234,"type":22},"2030-12-30",{"name":49,"class":50},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":140,"enrollmentInfo":242,"targetDuration":244,"studyType":23,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100606590","prospective-validation-study-of-a-uterine-fibroid-related-infertility-prediction-model-100606590","NCT07177534","Prospective Validation Study of a Uterine Fibroid-Related Infertility Prediction Model","Inclusion Criteria:\n\n* Women aged 20-50 years with recent desires for conception. Diagnosed with uterine fibroids via ultrasound or pathology. Complete clinical records available. Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active severe infectious or rheumatologic autoimmune diseases. History of malignant tumors. Incomplete clinical records. Unable to contact via phone or refusal to participate in follow-up.",{"count":243,"type":22},7084,"5 Years","Female fertility may be affected by uterine fibroids, although this association has not been elucidated. Our retrospective study has already constructed a predictive model for infertility risk in patients with uterine fibroids using machine learning. We will now validate and optimize this model through a prospective study",[247,27],"Uterine Fibroids",[249,27,250],"Uterine fibroids","Pregnancy rate","2025-09-16",{"date":253,"type":43},"2025-09-17",{"date":255,"type":22},"2025-09-30",{"date":257,"type":22},"2031-09-30",{"name":259,"class":50},"Tongji Hospital",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":267,"targetDuration":4,"studyType":60,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":51},"100519258","best-treatment-for-women-with-both-polycystic-ovary-syndrome-pcos-and-subclinical-hypothyroidism-100519258","NCT06041204","Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism","Letrozole Alone vs. Letrozole Plus Levothyroxine for Ovulation Induction in Infertile Women With Both (Polycystic Ovary Syndrome) PCOS and Sub-clinical Hypothyroidism.","Inclusion Criteria:\n\nAge between 20-40 years\n\nBMI between 18-35 kg\u002Fm2\n\nMeet diagnostic criteria for PCOS based on the Rotterdam consensus criteria and ESHRE\u002FASRM modifications (2018):\n\nOligo- and\u002For anovulation Clinical and\u002For biochemical signs of hyperandrogenism Polycystic ovaries on ultrasound\n\nSubclinical hypothyroidism defined as TSH level between 5-10 mIU\u002FL with normal free T4\n\nInfertility duration ≥ 1 year\n\nIntact ovaries and uterus, confirmed by physical exam and imaging\n\nNormal semen analysis in male partner\n\nNo tubal or peritoneal factor contributing to infertility\n\nEffective contraception if not attempting conception\n\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nKnown thyroid disease or on thyroid medications\n\nAbnormal thyroid function tests other than subclinical hypothyroidism\n\nHyperprolactinemia\n\nPresence of other causes of infertility such as:\n\nModerate to severe male factor infertility Bilateral tubal occlusion or peritoneal factors Stage III-IV endometriosis Ovarian failure or insufficiency (high FSH or low AMH)\n\nPrevious diagnosis of any type of congenital adrenal hyperplasia\n\nUncontrolled diabetes (HbA1C \\>8%)\n\nHistory of deep vein thrombosis or thromboembolic events\n\nAny contraindication to letrozole or levothyroxine\n\nPrevious use of letrozole or levothyroxine in past 6 months\n\nCurrent or suspected pregnancy\n\nBreastfeeding\n\nInability to comply with treatment and follow-up procedures",{"count":268,"type":22},200,[90],"The goal of this randomized controlled trial is to compare letrozole alone versus letrozole plus levothyroxine for ovulation induction in infertile women with both PCOS and subclinical hypothyroidism. The main questions it aims to answer are:\n\nIs letrozole plus levothyroxine superior to letrozole alone in achieving ovulation in these patients? Does combining levothyroxine with letrozole lead to higher pregnancy and live birth rates compared to letrozole alone?\n\nParticipants will be randomized into two groups:\n\nGroup 1 will receive letrozole only, starting at 2.5 mg daily from day 3 to 7 of the menstrual cycle. The dose will be increased up to 7.5 mg if no ovulation occurs, for a maximum treatment period of 6 months or until pregnancy is achieved.\n\nGroup 2 will receive letrozole at the same doses as group 1 plus 25 mcg levothyroxine daily.",[272,273,27],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Subclinical Hypothyroidism",[275,276,277,278],"Letrozole","Levothyroxine","PCOS","Subclinical hypothyroidism","2025-08-30",{"date":281,"type":43},"2025-09-03",{"date":283,"type":43},"2021-05-06",{"date":285,"type":22},"2026-06-28",{"name":287,"class":50},"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":60,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":51},"100323874","autologous-ovarian-tissue-transplantation-100323874","NCT03496636","Autologous Ovarian Tissue Transplantation","Inclusion Criteria:\n\n* Previously cryopreserved ovarian tissue\n* Ovarian insufficiency and\u002For candidate for pregnancy\n* Good health\n* Oncologist's clearance\n\nExclusion Criteria:\n\n* Patients considered to be high risk for surgical complications\n* Women with contraindication for pregnancy if goal is to achieve pregnancy\n* Women positive for the BRCA mutations\n* Women with a history of leukemia, ovarian cancer or a cancer that likely involved ovaries at the time of ovarian tissue collection\n* Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent\n* Current pregnancy","45 Years",{"count":296,"type":22},5,[90],"Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and\u002For radiation treatments.",[27],[301,302],"Ovary","Transplant","2025-08-12",{"date":305,"type":43},"2025-08-14",{"date":307,"type":43},"2021-03-01",{"date":309,"type":22},"2027-09-01",{"name":311,"class":50},"University of Pittsburgh",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":51},"100563030","surgical-and-obstetric-outcomes-in-patients-with-uterine-malformations-undergoing-hysteroscopic-corrective-treatment-100563030","NCT06610864","Surgical and Obstetric Outcomes in Patients With Uterine Malformations Undergoing Hysteroscopic Corrective Treatment","MAL_CO","Inclusion Criteria:\n\n* Women who underwent hysteroscopy at the Class Hysteroscopy Center of Policlinico Universitario A. Gemelli di Roma or Azienda Ospedaliera Universitaria Federico II di Napoli for the correction of uterine malformations, including partial, complete, and septate bicornuate uteri, dysmorphic uteri, with or without associated cervical and\u002For vaginal septa (ESHRE-ESGE classification: U1a and U1c; U2a, U2b, and U3c with or without associated cervical or vaginal anomalies C1\u002F2 or V1\u002F2).\n* Age 18 years or older.\n\nExclusion Criteria:\n\n* Patients with known, concurrent causes of infertility.\n* Patients who did not provide informed consent to participate in the study.\n* Age younger than 18 years.",{"count":320,"type":22},300,"The goal of this observational cohort study is to learn if hysteroscopic correction can improve reproductive outcomes in women with uterine malformations. The main questions it aims to answer are:\n\nPrimary hypothesis:\n\n-Does hysteroscopic correction significantly improve pregnancy rates at 12 months post-surgery in women with uterine malformations?\n\nSecondary hypotheses:\n\n* Does hysteroscopic correction significantly reduce the rate of first and second-trimester spontaneous abortions?\n* Does hysteroscopic correction significantly increase the live birth rate?\n* In symptomatic patients, does hysteroscopic correction significantly reduce dyspareunia and dysmenorrhea?\n* Which patient, histopathological, and surgical factors are associated with improved obstetric outcomes?\n\nResearchers will compare obstetric outcomes (pregnancy rate, spontaneous abortion rate, live birth rate, and symptom severity) before and after hysteroscopic correction to determine the effectiveness of this surgical intervention.\n\nParticipants will be women with uterine malformations who underwent hysteroscopic correction at the Digital Hysteroscopy Center of Policlinico Universitario A. Gemelli di Roma and Azienda Ospedaliera Universitaria Federico II di Napoli. Data will be retrospectively collected and analyzed to assess the impact of surgery on reproductive outcomes.",[323,27,324],"Malformation","Hysteroscopy Surgery",[326,327,328],"uterine malformation","hysteroscopic metroplasty","reproductive outcomes","2025-08-04",{"date":331,"type":43},"2025-08-05",{"date":333,"type":43},"2024-10-11",{"date":335,"type":22},"2025-10-11",{"name":337,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":60,"phases":348,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":51},"100598036","adipose-stem-cell-mitochondria-supplementation-to-oocytes-ascent-100598036","NCT07066267","Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)","Clinical Application of Autologous Adipose Stem Mitochondria Transplantation to Oocytes for Improving Embryo Quality in Patients With Recurrent Pregnancy Failure","Inclusion Criteria:\n\n* Having at least three previous failed IVF trial\n* Specifically consented for to collect biopsies for Preimplantation generic testing for aneuploidy (PGTA) analysis\n* Specifically consented for to have single blastocyst transfer (recommended)\n* No major uterine or ovarian abnormalities\n* Specifically consented for to have all embryos frozen\n* Specifically consented for to collect adipose tissues from subcutaneous liposuction\n* BMI level level \\\u003C26kg\u002Fm2\n\nExclusion Criteria:\n\n* Ovarian endometriosis with Chocolate cysts (American Fertility Society (AFS)) classification type 3 and 4\n* Any medical contraindication oocyte retrieval or subsequent procedures Ovarian hyperstimulation syndrome Bleeding disorders Sex hormone allergies Severe emotional defect on injections\n* Severe sperm abnormalities\n* \\\u003C5 million\u002FmL motile sperm\n* Uterine structural anomalies\n* Polycystic ovaries\n* Premature ovarian failure","29 Years","39 Years",{"count":5,"type":22},[90],"The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.",[27,351,352,353,354],"Oocyte Competence","Mitochondria","Recurent Implantation Failures","Advanced Age",[356,357,358,359,360],"mitochondria","mitochondria transplantation","Adipose stem cell","oocyte","Female infertility","2025-07-14",{"date":363,"type":43},"2025-07-17",{"date":365,"type":43},"2025-04-25",{"date":186,"type":22},{"name":368,"class":369},"Sunkaky Medical Cooperation","INDUSTRY",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":140,"enrollmentInfo":377,"targetDuration":4,"studyType":60,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":393},"100471629","effects-of-intrauterine-administration-of-autologous-pbmc-on-the-endometrial-cells-populations-100471629","NCT05421364","Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations","Effects of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells (PBMC) on the Endometrial Cells Populations","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Presenting altered endometrial immune profile\n* Having primary infertility\n* Having regular menstrual cycles\n* Embryo transfer of euploid embryos\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial Bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA\n* Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S\n* Cancer diagnostics\n* Positive HIV, HCV or HBV tests",{"count":320,"type":22},[90],"The behaviour of the endometrium during its receptive phase is highly dependent on the endometrial cell type composition. Each cell type has its role in the endometrial preparation for the invading embryo. Alteration in the immune cells dialogue could be the main reason for unsuccessful implantation in certain patients. Immune cell homeostasis is often improved by intrauterine administration of autologous PBMC.\n\nThere have been numerous reports on the positive effects of the intrauterine administration of autologous PBMC on the IVF outcomes (embryo implantation and ongoing pregnancy success). However, there is little data on the direct effect of the PBMC administration on the cell composition of the endometrium. This study will focus on the changes in the endometrial cell populations by PBMC treatment that could lead to IVF outcome improvement.\n\nThe aim of this project is to analyze the effect of intrauterine administration of autologous PBMC on the endometrial cell populations and on the IVF outcome parameters (implantation and ongoing pregnancy success as IVF outcome variables).",[27],[382,360,383,384],"Peripheral blood mononuclear cells (PBMC)","Endometrium","Endometrial cell populations","2025-05-20",{"date":387,"type":43},"2025-05-21",{"date":389,"type":43},"2023-12-09",{"date":391,"type":22},"2026-12-09",{"name":158,"class":50},2,{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":346,"enrollmentInfo":401,"targetDuration":4,"studyType":60,"phases":403,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":51},"100586900","phase-4-phase-iv-study-to-evaluate-the-efficacy-and-safety-of-fang-le-shu-compared-to-guo-na-fen-for-controlled-ovarian-stimulation-in-infertile-women-undergoing-in-vitro-fertilization-embryo-transfer-ivf-et-100586900","NCT06921395","Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).","A Phase IV, Prospective, Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Evaluate Efficacy and Safety of Fang Le Shu (Recombinant FSH) Versus Guo Na Fen Used for Controlled Ovarian Stimulation in Infertile Women Undergoing In Vitro Fertilization-Embryo Transfer.","Inclusion Criteria:\n\n* Is pre-menopausal female aged ≥20 to \\\u003C40 years.\n* Has regular menstrual cycles of ≥25 to ≤35 days.\n* Has Normal baseline serum FSH, LH, E2, P4.\n* Is able to voluntarily sign the informed consent form (ICF).\n* Has history of infertility for at least 1 year before the day of randomization; however, subjects with confirmed diagnosis of infertility are eligible without fulfilling the 1-year requirement.\n\nExclusion Criteria:\n\n* Has any known clinically significant major systemic disease, or endocrine or metabolic abnormalities with the exception of controlled thyroid function disease.\n* Has body mass index (BMI) of \\>30 kg\u002Fm2.\n* Has clinically significant abnormalities of the uterus, ovary, or appendix prior to the day of randomization\n* Has history of surgeries that may affect oocyte retrieval or pregnancy outcome, such as surgical resection of uterine mediastinum, fibroids, or cysts (however, patients who received polypectomy are allowed to enroll).\n* Has history of severe ovarian hyperstimulation syndrome (OHSS) defined as Grade 4 or higher.\n* Poor ovarian reponder according to Bologna criteria\n* Has plans to donate oocyte or recieve embryo from another women or undergo preimplantation genetic testing(PGT)\n* Has history of three or more failures in previous IVF cycles\n* Has history of recurrent miscarriage\n* Has known current active pelvic inflammatory disease.\n* Is currently breastfeeding.\n* Has a contraindication to pregnancy that would preclude participation in the trial.",{"count":402,"type":22},248,[404],"PHASE4","The aim of this randomized, open-label, active-controlled, parallel-group, multicenter, phase IV study is to assess the efficacy and safety of Fang Le Shu versus Guo Na Fen used for controlled ovarian stimulation in infertile women undergoing In Vitro Fertilization-Embryo Transfer.",[27],"2025-04-08",{"date":409,"type":43},"2025-04-10",{"date":411,"type":43},"2025-02-15",{"date":413,"type":22},"2026-06-30",{"name":415,"class":369},"LG Chem",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":423,"targetDuration":4,"studyType":60,"phases":425,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":393},"100585006","phase-1-evaluating-mechanically-engineered-stem-cell-exosomes-for-treating-endometrial-injury-a-clinical-study-100585006","NCT06896747","Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study","Evaluation of the Therapeutic Effects of Mechanically Engineered Umbilical Cord-Derived Stem Cell Exosomes on Endometrial Injury: A Prospective, Non-Randomized, Parallel-Controlled Clinical Study","Inclusion Criteria:\n\n1. Females aged 20-40 years (inclusive of boundary values);\n2. Normal ovarian reserve function (criteria: AFC ≥ 7, AMH \\> 1.1 ng\u002FmL);\n3. History of transcervical resection of adhesions (TCRA);\n4. Received PRP treatment after TCRA;\n5. At least one embryo transfer (ET) cycle in which they underwent standard ovarian stimulation (fresh cycle) or standard hormone replacement therapy (FET cycle), with an endometrial thickness of \\\u003C7 mm;\n6. Planned to continue IVF\u002FICSI\u002FFET-assisted conception;\n7. Able to accept and adhere to treatment and follow-up and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with severe systemic diseases, surgical contraindications, or cycle contraindications;\n2. Patients with reproductive tract infections, genital tuberculosis, pelvic inflammatory disease, or malignant tumors of reproductive organs;\n3. Patients with systemic diseases that cause uterine bleeding;\n4. Patients allergic to any drugs, materials, or components used in this study;\n5. Patients at high risk for hormone-dependent tumors such as breast cancer or ovarian tumors;\n6. Patients with untreated submucosal fibroids of any size (FIGO 0\u002FI\u002FII), uterine fibroids ≥5 cm (FIGO III, IV, V, VI, VII), adenomyosis, unicornuate uterus, bicornuate uterus, or endometrial polyps;\n7. Patients with hydrosalpinx ≥3 cm or hydrosalpinx of any size with significant vaginal discharge;\n8. Patients with ovarian endometriotic cysts (chocolate cysts) ≥4 cm;\n9. Patients who participated in other clinical trials within 3 months before surgery or during the study period;\n10. Patients unable to tolerate anesthesia;\n11. Patients with genetic abnormalities;\n12. Other patients deemed unsuitable for participation in this study by the investigator.",{"count":424,"type":22},90,[426,62],"PHASE1","The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium.\n\nThe main questions it aims to answer are:\n\nCan exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, which receives PRP via the same methods, to see if exosomes provide superior therapeutic effects.\n\nParticipants will:\n\nReceive either mechanical exosomesor or conventional esosomes or PRP through subendometrial injection.\n\nBe monitored for changes in endometrial parameters.",[429,27,430],"Thin Endometrial Lining","Intrauterine Adhesions","2025-03-19",{"date":433,"type":43},"2025-03-26",{"date":435,"type":43},"2025-02-21",{"date":437,"type":22},"2027-03-31",{"name":439,"class":50},"Tang-Du Hospital",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":115,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":447,"targetDuration":4,"studyType":60,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":459,"locationsCount":51},"100562158","phase-1-a-comparing-study-between-sj04-and-ovidrel-in-healthy-subjects-100562158","NCT06599528","A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects","A Phase I Clinical Trial to Compare the Pharmacokinetics, Safety and Immunogenicity of SJ04 and Ovidrel® in Healthy Female Subjects in China","Inclusion Criteria:\n\n1. Healthy female subjects aged 20 to 40 years old (including boundary values).\n2. Weight not less than 45.0 kg, body mass index within the range of 19.0\\~26.0 kg\u002Fm2 (including boundary values).\n3. Menstrual cycle regularity, or menstrual regularity before taking oral contraceptives (25-34 days, including boundary values).\n4. The levels of follicle stimulating hormone(FSH), luteinizing hormone(LH), prolactin (PRL), estradiol (E2), progesterone (P), and testosterone (T) detected within 2-3 days after the last menstrual period before the first administration are within normal ranges or considered abnormal by the researchers to have no clinical significance.\n5. LH levels \\<5 IU\u002FL, FSH levels \\<4 IU\u002FL at Day -1.\n\nExclusion Criteria:\n\n1. Allergy or suspected allergy to any component of the experimental drug, control drug, GnRH, GnRH analogs used in this study.\n2. Use of any LH preparation, human menopausal gonadotropin (hMG) or human chorionic gonadotropin (hCG) preparation within 3 months prior to screening.\n3. Previously or currently suffering from the following diseases: hypothalamic or pituitary tumors, unexplained ovarian enlargement or cyst, Abnormal uterine bleeding of unknown etiology, malignant tumors of the ovaries, uterus, or breast, active thromboembolic diseases, uncontrollable thyroid or adrenal dysfunction, endocrine disorders such as hyperprolactinemia, polycystic ovary syndrome, ovarian hyperstimulation syndrome (OHSS), and ovarian dysfunction, other malignant tumors or diseases of the hypothalamus, pituitary gland, ovaries, and uterus (excluding uterine fibroids).\n4. Ectopic pregnancy within 3 months prior to screening.\n5. Presence of clinically significant acute or chronic infection at screening or enrolment。\n6. Presence of localised disease affecting the hypodermic site, or inability to tolerate hypodermic injections。\n7. Difficulty in blood collection or inability to tolerate venipuncture, or history of needle or blood sickness.\n8. Prescription medications taken within 14 days or 5 half-lives prior to screening or over-the-counter medications (including proprietary and herbal medications) taken within 7 days or 5 half-lives prior to screening .\n9. A history of chronic or serious illness or disease of the liver, kidneys, gastrointestinal tract, endocrine system, cardiovascular, neurological, metabolic, haematological, respiratory, or autoimmune systems or an existing disease of one of the above systems which, in the judgement of the investigator, makes him or her unsuitable for enrolment.\n10. Abnormalities in vital signs, physical examination, laboratory tests (routine blood, blood biochemistry, urinalysis, coagulation, thyroid function), 12-lead electrocardiogram, liquid-based thin-layer cytometry (TCT), and ultrasound are judged by the investigator to be clinically significant and to warrant participation in the trial.\n11. Positive tests for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and syphilis spirochete antibody.\n12. History of mental illness, substance abuse, drug dependence, or positive substance abuse screen (morphine, THC, methamphetamine, MDMA, ketamine) on the day of admission.\n13. Excessive consumption of tea, coffee or caffeinated beverages in the 3 months prior to screening.\n14. Drinking an average of more than 14 standard units of alcohol per week in the three months prior to screening, or inability to abstain from alcohol during the test period, or a positive breathalyser test result on the day of admission.\n15. Smoke at least 5 cigarettes per day in the 3 months prior to screening or not be able to stop using any tobacco-based products during the trial.\n16. Participated in a clinical trial of another drug within 28 days prior to screening and used the test drug, or participated in a clinical trial of a medical device within 1 month prior to screening.\n17. History of blood donation or bleeding \\>400 ml within 3 months prior to screening.\n18. During pregnancy or breastfeeding, or a positive pregnancy test result. The subject (or his\u002Fher partner) is planning to have children (including sperm and egg donation) throughout the trial period and for 3 months after the end of the trial. Unwilling to use one or more non-pharmacological contraceptive methods (e.g. total abstinence, condoms, ligation, etc.) during the trial period.\n19. Subjects who withdrew from the trial for their own reasons and who, in the opinion of the investigator, were otherwise unsuitable to participate in the trial.",{"count":448,"type":22},48,[426],"This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.",[452,27],"Assisted Reproductive Technology","2025-02-05",{"date":455,"type":43},"2025-02-10",{"date":457,"type":43},"2024-08-12",{"date":186,"type":22},{"name":460,"class":369},"Suzhou Centergene Pharmaceuticals Co.,Ltd.",{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":468,"maxAge":167,"enrollmentInfo":469,"targetDuration":4,"studyType":60,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":51},"100564473","investigate-the-efficacy-of-using-nmn-to-improve-embryo-development-capacity-100564473","NCT06629636","Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.","Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity and IVF Success Rate in Patients Who Have Experienced IVF Failures.","Inclusion Criteria:\n\n* Agree to participate in the study\n* 32-42 years old\n* Having at least one previous embryo implantation failure\n* History of low Embryo quality at day3 or day5 (according to Veeck's and Gardner's Criteria)\n* No major uterine or ovarian abnormalities\n* BMI level 18-25kg\u002Fm2\n\nExclusion Criteria:\n\n* Ovarian endometriosis with Chocolate cysts (AFS type 3 and 4)\n* Patients who have taken different supplements such as coenzyme Q10, vitamin E, carnitine,niacin, nicotinamide, or other vitamin B3-related etc. within the previous month\n* Any medical contraindication of oocyte retrieval or subsequent procedures\n* Couples where the husband presents with severe sperm abnormalities\n* Couples where the husband presents \\<5 million\u002FmL motile sperm\n* Uterine structural anomalies\n* Polycystic ovaries\n* Premature ovarian failure\n* Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.\n* Individuals who need drug treatment for any mental illness such as epilepsy and depression.\n* Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.\n* Cancer patients or receiving chemo\u002Fradiotherapy treatment within the past 3 years.","32 Years",{"count":221,"type":22},[90],"The objective of this study is to investigate the efficacy of NMN supplementation in enhancing embryo developmental capacity and improving IVF success rates in patients experiencing IVF failures.",[473,27],"Repeated IVF Failure",[475,476,27,477,478,479],"IVF failure","NMN","Japan","Oocyte Mitochondria","Anti aging","2024-10-03",{"date":482,"type":43},"2024-10-08",{"date":484,"type":43},"2024-08-20",{"date":186,"type":22},{"name":368,"class":369},{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":498,"conditions":499,"keywords":500,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":51},"100428996","female-fertility-environmental-agents-and-stress-oxidant-100428996","NCT04866329","Female Fertility, Environmental Agents and Stress Oxidant","FERTilité féminine, Agents ENvironnementaux et Stress OXydant","FERTENOX","Inclusion Criteria:\n\n* Woman aged 18 to 43 years old\n* First oocyte puncture (IVF rank = 1)\n\nExclusion Criteria:\n\n* Opposition to data processing\n* IVF rank equal or greater than 2\n* Egg donation\n* Intracytoplasmic Sperm Injection with testicular biopsy\n* Intracytoplasmic Sperm Injection with self-preservation straw\n* Sperm donation","43 Years",{"count":497,"type":22},500,"Synthetic products used in industrial, pharmaceutical, agro-alimentary or agricultural fields are found in our environment. Thus, humans could be simultaneously exposed to several of these pollutants. Furthermore, these environmental agents exert or could exert adverse actions on fertility, by altering gamete and embryo quality through endocrine disruptor effects or through increase in oxidative stress in gonads (cellular pathway known to be involved in several human reproductive pathologies).\n\nIn this context, the objectives of the present project are to obtain descriptive and analytical data on woman and oocyte exposure to several environmental agents (bisphenols, ethynylestradiol and glyphosate). The relation between these pollutant measures in follicular fluid and urine (from women receiving follow-up of in vitro fertilization (IVF) protocol in the University hospital of Tours, France) and the oocyte quality, the IVF and pregnancy successes will be studied. Several oxidative stress biomarkers in blood and follicular fluid will be also measured for these women, who will complete a questionnaire on their lifestyles. Finally, thanks to in vitro approaches, the effects and the mechanisms of action (including oxidative stress) of these pollutants (alone or in cocktails) will be studied on granulosa cells from these patients.",[27],[501,502,503,504,505,506,507,508,509],"Environmental pollutants","Bisphenols","Ethynylestradiol","Glyphosate","Oxidative stress","Oocyte and embryo quality","In vitro fertilization","Pregnancy","Follicular fluid and urine biomarkers","2024-07-24",{"date":512,"type":43},"2024-07-25",{"date":514,"type":43},"2021-12-08",{"date":516,"type":22},"2027-12",{"name":518,"class":50},"University Hospital, Tours",{"id":520,"slug":521,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":495,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":51},"100523653","looking-for-a-blood-epigenetic-signature-to-predict-female-infertility-100523653","NCT06098495","Looking for a Blood Epigenetic Signature to Predict Female Infertility","FIB_CARIPLO","Inclusion Criteria:\n\n* 18\\\u003C age \\\u003C43, Infertile woman undergoing ART, recurrent pregnancy loss\n\nExclusion Criteria:\n\n* age \\\u003C 18 or \\> 44, previous ovarian surgery, severe male factor infertility",{"count":527,"type":22},1456,"The present research project aims to study the DNAm mechanisms underlying the reduction of fertility due to the progressive depletion of oocyte quality. Specifically, our project aims to build an epigenetic clock for MGCs by using outcomes that are certainly related to female fertility. The validation of such findings will be carried out on peripheral blood in order to guarantee its non-invasiveness and allow for any clinical transferability. In order to identify a blood epigenetic signature able to predict female infertility, we planned to explore the problem from different points of view by conducting several studies in different settings.",[27],"2023-10-18",{"date":532,"type":43},"2023-10-24",{"date":534,"type":43},"2023-10-16",{"date":536,"type":22},"2026-10-16",{"name":538,"class":50},"Università Vita-Salute San Raffaele"]